PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50325F80035Purchase ciprofloxacin 250mg 5ml ORAL suspension — Bayer Healthcare Pharmaceuticals Inc

Bayer Healthcare Pharmaceuticals Inc holds $14.3M across 87 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 36F79720D0237. Competition previously drew 3 offers. Recompete timing centers on the Sep 29, 2026 PoP end — agencies typically plan 12–18 months ahead.

Aspr/Orm-Sns
Awarding office
Bayer Healthcare Pharmaceuticals Inc
Recipient
Sep 29, 2026
PoP end
$15.1M
Obligated
$15.1M
Potential
325412
NAICS
6505
PSC
3 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Bayer Healthcare Pharmaceuticals Inc — $90

Contract facts

Federal
Contract number75A50325F80035
Also listed as36F79720D0237-75A50325F80035
AgencyAspr/Orm-Sns
Awarding officeAspr/Orm-Sns
Awarding agencyDepartment of Health and Human Services (HHS)
Funding agencyDepartment of Health and Human Services (HHS)
IncumbentBayer Healthcare Pharmaceuticals Inc
CAGE59463
UEIV1EVGCK7XES8
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV36F79720D0237
Place of performanceWHIPPANY NJ
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startSep 30, 2025
PoP end (current)Sep 29, 2026
Obligated$15.1M
Current value$15.1M
Potential value$15.1M

PURCHASE CIPROFLOXACIN 250MG/5ML ORAL SUSPENSION, POWDER, 100ML BOTTLE is a federal award for Aspr/Orm-Sns held by Bayer Healthcare Pharmaceuticals Inc. Estimated value $15.1M ($15.1M obligated). Current period of performance ends Sep 29, 2026. Last award drew 3 bidders. Place of performance: WHIPPANY NJ.

PURCHASE CIPROFLOXACIN 250MG/5ML ORAL SUSPENSION, POWDER, 100ML BOTTLE

Recompete timing

Public
Expiring in 39 days

Current PoP ends Sep 29, 2026 (39 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Bayer Healthcare Pharmaceuticals Inc$14.3M obligated across 87 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($14.3M) · all agencies
Department of Health and Human Services (HHS)$15.1M · 106%Department of Defense (DOD)$387K · 3%Department of Justice (DOJ)$345K · 2%
Open full company profile

Related awards

Same parent · incumbent
36C26226F0163
XOFIGO - RADIUM RA 223DICHLORIDE INJ
$181K
Mar 31, 2027
SPE2D026F0101
8511938413!OTHER MEDICAL
$120K
Apr 5, 2027
36C25626N0492
XOFIGO RADIUM 223 FOR CANCER TREATMENT.
$387K
Apr 9, 2027
36C24723F0573
RA-223 DICHLORIDE XOFIGO RADIO PHARM
$264K
Jun 30, 2028
36C25626N0126
RADIUM FOR CANCER TREATMENT
$376K
Aug 20, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 75A50325F80035?

75A50325F80035 (Purchase ciprofloxacin 250mg 5ml ORAL suspension) is a Aspr/Orm-Sns award with a potential value of $15.1M, currently held by Bayer Healthcare Pharmaceuticals Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50325F80035?

Aspr/Orm-Sns awarded 75A50325F80035 to Bayer Healthcare Pharmaceuticals Inc (potential $15.1M).

Who is the incumbent on 75A50325F80035?

Bayer Healthcare Pharmaceuticals Inc is the incumbent with $14.3M across 87 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2026.

When does Bayer Healthcare Pharmaceuticals Inc’s 75A50325F80035 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 29, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50325F80035